Information  X 
Enter a valid email address

Oxford Glycosciences (OGS)


Tuesday 01 April, 2003

Oxford Glycosciences

Celltech announcement

Oxford Glycosciences PLC
01 April 2003

01 April 2003

Not for release, publication or distribution in, into or from Australia, Canada
or Japan

               OXFORD GLYCOSCIENCES PLC ('OGS' or the 'Company')


OGS notes today's announcement by Celltech Group plc ('Celltech') relating to
the level of acceptances received for the Celltech offer.

In particular, OGS notes that Celltech received acceptances in respect of a
total of 2,161,947 OGS shares (including those represented by OGS ADSs), which
together with the 5,892,971 OGS shares previously purchased by Celltech
represents approximately 14.4 per cent. of the issued share capital of OGS. In
addition, OGS notes that the Celltech offer has been extended and will remain
open for acceptance until 3.00 p.m. (London time), 10.00 a.m. (New York time) on
Tuesday, 15 April 2003.

Commenting, David Ebsworth PhD, CEO of OGS said 'We are pleased that our
shareholders have followed the Board's* advice and continue to support our
strategy of seeking higher offers for the Company.'


For further information please contact:

Oxford GlycoSciences Plc                                  +44 (0) 1235 208 000
David Ebsworth, Ph.D., Chief Executive Officer

Goldman Sachs International                               +44 (0) 20 7774 1000
Michael Hill
Basil Geoghegan
Phil Raper (Corporate Broking)

Financial Dynamics
UK Media and Investors                                    +44 (0) 20 7831 3113
Tim Spratt
Melanie Toyne-Sewell

US Media and Investors                                    +1 212 850 5626
Leslie Wolf-Creutzfeldt
Deborah Ardern Jones

Goldman Sachs International is acting for OGS and for no-one else in connection
with this announcement and will not be responsible to any other person for
providing the protections afforded to clients of Goldman Sachs International or
for providing advice in relation to the offer from Celltech, the merger with
Cambridge Antibody Technology Group plc ('CAT') or the contents of this

The directors of OGS accept responsibility for the information contained in this
announcement.  To the best of the knowledge and belief of the directors of OGS
(who have taken all reasonable care to ensure that such is the case), the
information contained in this announcement is in accordance with the facts and
does not omit anything likely to affect the import of such information.*

*Dr Donald Drakeman, a director of OGS, is also the Chief Executive Officer of
Medarex Inc, a competitor of CAT, and therefore did not participate in decisions
of the OGS Board relating to the merger with CAT.  Given this conflict, he has
also not participated and does not propose to participate in discussions
relating to any competing offer for OGS.  Accordingly, Dr Drakeman has abstained
from OGS Board discussions of, and advice to OGS shareholders relating to, the
merger with CAT and the offer from Celltech and is not taking responsibility for
the views or advice of the Board on the merger with CAT or the offer from

Shareholders can obtain a free copy of this and any other documents filed with
the Securities and Exchange Commission at the SEC's website (

This announcement does not constitute an offer to sell or invitation to purchase
any securities or the solicitation of any vote or approval in any jurisdiction.

The release, publication or distribution of this announcement in certain
jurisdictions may be restricted by law and therefore persons in such
jurisdictions into which this announcement is released, published or distributed
should inform themselves about and observe such restrictions.

                      This information is provided by RNS
            The company news service from the London Stock Exchange                                                                                                                                                                                                                   

a d v e r t i s e m e n t